A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Phase of Trial: Phase III
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Relamorelin (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Allergan
- 22 Jun 2018 Planned End Date changed from 5 Apr 2022 to 6 Dec 2020.
- 22 Jun 2018 Planned primary completion date changed from 5 Apr 2022 to 6 Dec 2020.
- 07 Feb 2018 New trial record